Intensive Care Research

Volume 1, Issue 1-2, June 2021, Pages 24 - 30

Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19

Authors
Yu Chen, Xijing Zhang*
Department of Critical Care Medicine, Xijing Hospital, Air Force Military Medical University, 15th Changle West Rd, Xi’an 710032, Shaanxi, China
*Corresponding author. Email: zhangxj918@163.com
Corresponding Author
Xijing Zhang
Received 19 January 2021, Accepted 6 April 2021, Available Online 10 April 2021.
DOI
https://doi.org/10.2991/icres.k.210406.001How to use a DOI?
Keywords
COVID-19, Tocilizumab, preliminary efficacy, safety
Abstract

Background: Interleukin-6 (IL-6) was considered to be with the severity and mortality in COVID-19 patients, which implies a potential therapeutic target for treatment. We aimed to evaluate the safety and initial efficacy of Tocilizumab treatment for COVID-19 patients.

Methods: In the retrospective study, 61 patients with COVID-19 with the mean age of 69 were enrolled from February 27 to March 14, 2020 in Wuhan Huoshenshan Hospital. Twenty-nine of them received one dose (400 mg) of add-on Tocilizumab treatment as the treated group and remaining 32 cases served as control group. The clinical manifestations and laboratory examinations were compared between the two groups.

Results: The average duration of symptoms appeal to hospital admission was 28.2 days. Compared with the cases in control group, the treated cases exhibited a significant increase of serum IL-6 on the 7th day since Tocilizumab injection, however, there were no differences in whole blood white cell count, circulating lymphocyte count, serum C-reactive protein (CRP), and respiratory parameters or other clinical manifestations between the treated and control groups. There were no adverse events associated with Tocilizumab treatment in the treated COVID-19 patients.

Conclusion: In the patients with COVID-19, one dose of Tocilizumab treatment was safe but no clinical benefit was observed on the 7th day in this study.

Chinese Abstract

背景:白细胞介素 6 (IL-6)表达水平与COVID-19 患者疾病严重程度和病死率密切相关,是临床治疗潜在治疗靶点。 我们旨在评估托珠单抗治疗 COVID-19 患者的安全性和有效性。

方法:回顾性研究中,2020年2月27日至3月14日在武汉火神山医院招募了61名平均年龄为69岁的COVID-19患者。其中治疗组29例患者在常规治疗基础上给予托珠单抗(400mg),其余32例作为对照组。比较两组临床表现及实验室检查。

结果:入院后临床症状持续时间平均为28.2天。与对照组相比,托珠单抗治疗后第7天,治疗组患者IL-6显著升高,但白细胞计数、淋巴细胞计数、血清C反应蛋白(CRP)无差异。且治疗组和对照组在呼吸参数及其他临床表现上无明显差异。在接受托珠单抗治疗的COVID-19 患者中,未发生与托珠单抗治疗相关的不良事件。

结论:在 COVID-19 患者中,托珠单抗治疗是安全的,但在本研究的未观察到临床获益。

Copyright
© 2021 First Affiliated Hospital of Zhengzhou University. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Intensive Care Research
Volume-Issue
1 - 1-2
Pages
24 - 30
Publication Date
2021/04/10
ISSN (Online)
2666-9862
DOI
https://doi.org/10.2991/icres.k.210406.001How to use a DOI?
Copyright
© 2021 First Affiliated Hospital of Zhengzhou University. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Yu Chen
AU  - Xijing Zhang
PY  - 2021
DA  - 2021/04/10
TI  - Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
JO  - Intensive Care Research
SP  - 24
EP  - 30
VL  - 1
IS  - 1-2
SN  - 2666-9862
UR  - https://doi.org/10.2991/icres.k.210406.001
DO  - https://doi.org/10.2991/icres.k.210406.001
ID  - Chen2021
ER  -